Ocuphire Pharma Investor Update

RM 33 Reversal of Mydriasis (RM) Market Opportunity With No Commercially Available Treatment, Nyxol May Achieve Significant Revenue Potential GlobalData Market Research Findings 100M Annual Eye Dilations 80% of Patients Likely to Request Drop MIRA Trials Represent 95% of Dilation Drops Used in Practice Patient Willingness to Pay $10 - $20+ 65% Report Moderate to Severe Impact to Daily Function ~$500+M Estimated US RM Market Opportunity Source: GlobalData Market Research Survey Calculation: 100M Annual Eye Dilations X 65% X 80% X $10 per patient = $500+M Opportunity 58% physicians would start prescribing Nyxol within 1st year 81% patients would be more likely to schedule yearly eye exams with a reversal drop 0 Current Commercially Available Treatments 68% physicians would be willing to use Nyxol even if patients had to still wear sunglasses within 1st hour Ocuphire PHARMA

View entire presentation